News ArchivesRead News
Parkinson’s Drug Trial Has Researchers Optimistic
Thursday July 31, 2014
Chicago Sun Times - Results of a Phase I clinical trial of what could be the first vaccine for Parkinson’s disease has experts cautiously optimistic.
Those results were released Thursday by the maker of the drug and the Michael J. Fox Foundation for Parkinson’s Disease.
The disease, a progressive disorder of the nervous system that affects movement, is believed to be caused by abnormal deposits in the brain of a protein that helps nerve cells talk to each other.
Many drugs can make movement easier or alleviate other symptoms of the disease. But no drug has been shown to effectively slow or stop the progression.
The drug being tested is known as PD01A, made by AFFiRiS AG, an Austria-based biotech company. It is supposed to stimulate the body’s immune system to produce antibodies that bind to the protein alpha-synuclein, clearing it from the brain and slowing disease progression.
Phase 1 looked only at whether PD01A was safe and tolerable to the relatively small sample of 32 people with Parkinson’s disease. The drug passed that test.
It was also found to generate alpha-synuclein-specific antibodies in 50 percent of the patients. If that is duplicated on a larger population, it could be a breakthrough for Parkinson’s disease.
“A treatment that could slow or stop Parkinson’s progression would be a game-changer for the five million worldwide living with this disease and the many more who will become at risk as our population ages,” Todd Sherer, CEO of the Michael J. Fox Foundation, said in a statement. The most recent drug trial “is one of the most promising efforts toward that goal.”
Dr. Christopher Goetz, director of the Parkinson’s Disease and Movement Disorders Center at Rush University Medical Center, agreed Phase I of PD01A is “very promising.”
But Goetz, who was not involved in the study, also cautioned that because testing of this drug is in the early stages, it remains to be seen whether increasing antibodies to fight alpha-synuclein actually does anything to effectively treat Parkinson’s disease.
Indeed, not everyone is convinced of that premise. And the findings are considered preliminary because they haven’t been published in a peer-reviewed medical journal.
Dr. Jose Biller, chair of the neurology department at Loyola Medicine, said he was cautiously optimistic at what could wind up being a “significant advance” in how Parkinson’s disease is treated.
“The basic science that is behind this trial is quite robust. And therefore, while nobody can talk about guarantee ….I think that it is a very cogent approach,” he said.
That said, though, Biller, who was not involved in the study, said, “We need to wait for the [follow-up] results.”
The next study will take place in Vienna and focus on assessing the immunological and clinical effects of a boost vaccination. Recruitment is expected to begin September.
Recent NewsOct 17 - Scientists Identify Structure of PINK1, Key Parkinson’s-protective Protein
Oct 17 - Diabetes drug cuts Parkinson's risk by 28 percent, study finds
Oct 10 - Advances in Brain Pacemaker Reduces Tremors, Helps Parkinson's Sufferers Live a More Normal Life
Oct 10 - Medical History Could Help Predict Parkinson's Disease Risk Long Before Diagnosis
Oct 3 - Changes in Olfactory Bulb Explain Loss of Smell in Early Stages of Parkinson’s Disease, Study Finds
Oct 3 - Sleep Disturbances May Worsen Motor Symptoms in Parkinson’s Disease, Study Suggests
Sep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show
Aug 14 - 16 Tips to Increase Your Mobility Confidence While Living With Parkinson’s Disease
Aug 10 - Boxers are fighting back against Parkinson’s